Benitec Biopharma Inc. develops clinical-stage genetic medicines based on its proprietary Silence and Replace DNA-directed RNA interference platform. The company’s lead program, BB-301, is a silence-and-replace therapeutic in development for dysphagia in patients with Oculopharyngeal Muscular Dystrophy, or OPMD.
Company news primarily covers BB-301 clinical development, including Phase 1b/2a study updates, follow-up data from treated cohorts, safety and clinical-activity observations, and presentations at gene therapy and muscular dystrophy medical meetings. Benitec also issues periodic financial results and operational updates tied to its development-stage biotechnology business.
Benitec Biopharma (NASDAQ: BNTC) reported Q2 FY2026 results and clinical progress for BB-301 for OPMD-related dysphagia.
All four Cohort 1 completers were formal responders at 12 months; Patient 1 showed deepening benefit at 24 months. Cohort 2 interim update and an FDA meeting on pivotal design are planned mid-2026. Cash was $189.0M at Dec 31, 2025; net loss was $11.8M (−$0.26/sh).
Benitec Biopharma (NASDAQ: BNTC) reported positive long-term results from the BB-301 Phase 1b/2a study in oculopharyngeal muscular dystrophy (OPMD). The first patient in Cohort 1 completed a 24-month follow-up and showed durable, deepening improvements in swallowing function versus pre-treatment and 12-month assessments.
Key objective measures improved and/or deepened at 24 months: PhAMPC +27% (maintained), NRRSv -60%, TPR -39%, and patient-reported SSQ -78%. All 4 Cohort 1 completers met prespecified responder criteria at month 12.
Benitec Biopharma (NASDAQ: BNTC) reported Q1 2026 results on Nov 14, 2025 and provided updates on its BB-301 program for Oculopharyngeal Muscular Dystrophy (OPMD).
Clinical: BB-301 achieved positive Phase 1b/2a interim results with a 100% responder rate (6/6) in Cohort 1; the FDA granted Fast Track Designation and the first patient in Cohort 2 was treated in Q4 2025.
Financing & cash: Completed an oversubscribed equity offering grossing ~$100 million on Nov 5, 2025; cash and cash equivalents were $94.5 million as of Sep 30, 2025.
Financials: Q1 total operating expenses were $9.8M vs $5.8M a year earlier; net loss attributable to shareholders was $9.0M or $(0.22) per share for the quarter.
Benitec Biopharma (NASDAQ: BNTC) announced a proposed underwritten public offering of common stock (or pre-funded warrants) and a concurrent registered direct offering with long-term investor Suvretta Capital. The company will grant underwriters a 30-day 15% overallotment option. The offerings are expected to close on November 7, 2025, subject to customary closing and market conditions. The SEC declared effective a Form S-3 registration on September 29, 2025. Leerink Partners, TD Cowen and Evercore ISI are bookrunning managers. A prospectus supplement will be filed with the SEC and offering materials will be available from the bookrunners and the SEC website.
Benitec Biopharma (NASDAQ: BNTC) reported positive interim results from the BB-301 Phase 1b/2a trial and said the FDA granted Fast Track designation for BB-301 for treatment of OPMD with dysphagia. All six patients in Cohort 1 met the formal statistical criteria for response (a 100% response rate).
Cohort 1 showed sustained improvements in dysphagic symptom burden, post-swallow residue, timed drinking capacity, and pharyngeal closure. BB-301 has prior Orphan Drug designations from both FDA and EMA. First patient in Cohort 2 was treated in Q4 2025. Benitec plans an FDA meeting in 2026 to confirm pivotal study design.
Benitec Biopharma (NASDAQ: BNTC) appointed Dr. Sharon Mates to its board of directors, effective November 2, 2025. Dr. Mates previously co-founded and served as CEO and chairman of Intra‑Cellular Therapies from 2002 until its ~$14.6 billion acquisition by Johnson & Johnson in 2025. She led development efforts that included FDA approval of CAPLYTA in 2019. Benitec said her experience will support progression of its BB‑301 OPMD program and broader development of its ddRNAi platform.
Benitec Biopharma (NASDAQ: BNTC) will provide a clinical update on BB-301, its gene therapy candidate for Oculopharyngeal Muscular Dystrophy (OPMD).
The company said it will report results for the six patients treated in Cohort 1 of the Phase 1b/2a study and host an investor webcast on November 3, 2025 at 8:00 am EST.
Webcast registration was posted by the company for investor access to the update.
Benitec Biopharma (NASDAQ: BNTC) released its full year 2025 financial results and provided updates on its BB-301 clinical program for OPMD treatment. The company reported a net loss of $37.9 million ($1.05 per share) compared to $22.4 million in 2024. Total expenses increased to $41.8 million, with R&D expenses at $18.3 million and G&A expenses at $23.4 million.
Key operational highlights include a favorable DSMB recommendation to continue enrollment into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study, expected to begin in Q4 2025. The company maintains a strong financial position with $97.7 million in cash and cash equivalents as of June 30, 2025. Interim clinical results for Cohort 1 are anticipated in Q4 2025.
Benitec Biopharma (NASDAQ: BNTC) has announced significant progress in its Phase 1b/2a Clinical Treatment Study for BB-301, its gene therapy treatment. The company successfully completed treatment of the sixth and final subject in Cohort 1 with a low dose of BB-301 in April 2025.
The Independent Data Safety Monitoring Board (DSMB) has completed its review of all six subjects in Cohort 1 and recommended continuation of subject enrollment. Following this positive recommendation, enrollment for Cohort 2 is expected to begin in Q4 2025. The company reports encouraging results regarding BB-301's safety profile, particularly noting the benefits of their local direct intramuscular delivery method.